Pan-HDAC inhibitors are used for the treatment of certain types of cancers, and many show promising results in preclinical models for T cell–mediated and neurological diseases (Falkenberg and Johnstone, 2014). The gene discussed is HDAC9; the disease is nervous system disorder.